Phenelzine

Phenelzine

SCHEMBL3602263

NNCCc1ccccc1.[Cl-].[H+]

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MAOAMAOB

The experimentally established mechanism targets of Phenelzine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA known ✓ P21397 2/20 0.91
MAOB known ✓ P27338 2/20 0.91
LMNA P02545 3/20 0.91
CYP3A4 P08684 3/20 0.91
SMN1; SMN2 Q16637 3/20 0.91
ALDH1A1 P00352 2/20 0.91
IDO1 P14902 2/20 0.91
KDM1A O60341 2/20 0.91
NPC1 O15118 2/20 0.91
RAB9A P51151 2/20 0.91
CYP1A2 P05177 2/20 0.91
CYP2D6 P10635 2/20 0.91
CYP2C19 P33261 2/20 0.91
HTR1A P08908 1/20 0.91
ADRA2A P08913 1/20 0.91
CYP2C8 P10632 1/20 0.91
CYP2C9 P11712 1/20 0.91
TSHR P16473 1/20 0.91
NFKB1 P19838 1/20 0.91
PTGS1 P23219 1/20 0.91

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenelzine SCHEMBL34335 0.95 LMNA (1.00) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1
Phenelzine SCHEMBL3644150 0.95 LMNA (1.00) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1
Phenelzine SCHEMBL6064850 0.93 LMNA (0.95) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1
Phenelzine SCHEMBL21084303 0.93 LMNA (0.95) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1
Phenelzine SCHEMBL2786042 0.93 CYP3A4 (0.95) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1
Phenelzine SCHEMBL118234 0.93 CYP3A4 (0.95) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1
Phenelzine SCHEMBL3243562 0.83 LMNA (1.00) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1
Phenelzine SCHEMBL40652 0.83 LMNA (1.00) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1
Phenelzine SCHEMBL5072466 0.83 LMNA (1.00) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1
Phenelzine SCHEMBL6428409 0.82 ALDH1A1 (0.83) LMNACYP3A4SMN1; SMN2ALDH1A1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230111917-A1 KINASE ANTAGONISTS UNIV CALIFORNIA (US) 2023-04-13 US disclosed
EP-2551270-B1 PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS UNIV CALIFORNIA (US) 2019-06-12 EP disclosed
US-8642604-B2 Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-02-04 US disclosed
EP-2004654-B1 PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS KINASE ANTAGONISTS UNIV CALIFORNIA (US) 2013-05-22 EP disclosed
EP-2551270-A2 PYRAZOLOPYRMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS The Regents of The University of California (US) 2013-01-30 EP disclosed
US-20110301144-A1 Kinase Antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-12-08 US disclosed
US-20100009963-A1 KINASE ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-01-14 US disclosed
US-7585868-B2 Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-09-08 US disclosed
EP-2004654-A2 KINASE ANTAGONISTS The Regents of the University of California (US) 2008-12-24 EP disclosed
US-20070293516-A1 Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-12-20 US disclosed
WO-2007114926-A2 KINASE ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293516-A1 Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine MTOR, PI4KA, PIK3CA MAOA 2544/4885MAOB 2808/4885LMNA 4705/4885
US-20230111917-A1 KINASE ANTAGONISTS MTOR, RPS6KA3, AKT3 MAOA 4006/4885MAOB 3886/4885LMNA 4806/4885
US-20100009963-A1 KINASE ANTAGONISTS MTOR, RPS6KA3, AKT3 MAOA 4006/4885MAOB 3886/4885LMNA 4806/4885
US-20110301144-A1 Kinase Antagonists MTOR, RPS6KA3, AKT3 MAOA 4006/4885MAOB 3886/4885LMNA 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.